Evidence map›Paper›PMID 41041069›Full record

ReviewTheranostics2025

Hot-spot empowered gold nanoparticles for theranostics in breast cancer.

Meng Tian, Shiqi Hu, Wen Sun, Ying Hu, Xingyi Ma

Abstract readReview
In one paragraph

Review in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meng TianSchool of Biomedical Engineering & School of Science, Harbin Institute of Technology, Shenzhen, 518055, China.
Shiqi HuShenzhen Keyto Fluid Technology Co., Shenzhen, 518100, China.
Wen SunCentre for Translational Medicine, Shenzhen Bao'an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, 518108, China.
Ying HuSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.
Xingyi MaSchool of Biomedical Engineering & School of Science, Harbin Institute of Technology, Shenzhen, 518055, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer, being the most prevalent malignant tumor among women, confronts severe challenges in its early detection and precise treatment. Traditional diagnostic approaches have drawbacks in terms of sensitivity and specificity, and are invasive, thereby making it arduous to satisfy practical demands. Nanomedicine has introduced novel diagnostic and therapeutic modalities for breast cancer, particularly gold nanoparticles (AuNPs), which have been utilized on account of their distinctive optical and physicochemical attributes. Hot-spot empowered AuNPs have rapidly emerged and demonstrated significant potential in the diagnosis and treatment of breast cancer. From a technical standpoint, the design and synthesis of AuNPs hot-spot are constantly evolving, ranging from the control of number to the control of structure and efficient control of hot-spot utilizations, establishing a development model of "number-structure-efficient utilization". Hot-spot empowered AuNPs are extensively employed in diagnosis and therapy, facilitating targeted drug delivery, photothermal and photodynamic therapy, and multimodal integration therapy, and also achieving the function of theranostics in an innovative manner. We have deliberated on the challenges and future development prospects of precision medicine for the diagnosis of early breast cancer and individualized treatment.

Indexed as

Breast NeoplasmsGoldMetal NanoparticlesTheranostic NanomedicineAnimalsDrug Delivery SystemsFemaleHumansPhotochemotherapyPhotothermal TherapyGoldbreast cancergold nanoparticleshot-spotnanostructural designtheranostics

Identifiers

PMID41041069
PMCPMC12486401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.